5 Things You Should Know Before Starting Ketamine Infusions for Bipolar Depression

If you are considering ketamine infusions for bipolar depression, you should know that according to a study published in the journal Expert Opinion on Drug Safety, ketamine is generally well tolerated and safe when administered mainly as an acute treatment (Rodrigues NB, McIntyre RS, Lipsitz O, et al. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. Expert Opin Drug Saf. doi: 10.1080/14740338.2020.1776699), but before you talk to your doctor about it, here are 5 things you should know.

Ketamine and Bipolar Depression

Writing in the September 2015 edition of The Lancet, Tony Kirby’s “Ketamine for Depression: the highs and lows” best articulates the pros and cons of off-label ketamine therapy to treat depression. After speaking with ketamine pioneers like Dr David Feifel, a psychiatrist at the University of California, San Diego and one of the first clinicians to use ketamine off-label as well as Dominic Sisti, an assistant professor in the Department of Medical Ethics and Health Policy at the Perelman School of Medicine, University of Pennsylvania, Kirby sums up the key ethical dilemma facing both patients and practitioners as  “balancing between prescribing ketamine off-label to patients with depression against making all patients wait until ketamine or a derivative is licensed for depression”. If you have only recently started to consider ketamine as means to manage manic depression, it is  important to understand and explore:

  • The potential of treating bipolar depression disorders with ketamine type drugs;
  • The history of ketamine;
  • How ketamine works within the human nervous system; and,
  • The role of glutamate and neuroplasticity.
Bipolar disorders with ketamine infusions
Can you manage bipolar disorders with ketamine infusions?

Bipolar disorder, formerly called manic depression, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). Symptoms can include an extremely elevated mood called mania as well as episodes of depression. People with bipolar disorder may have trouble managing everyday life tasks at school or work, or maintaining relationships. There’s no cure, but there are many treatment options, including using ketamine infusions to manage bipolar depression.

1. History of Ketamine for Depression

During the 1950’s and 60s, ketamine and a number of related drugs were created in the search for a drug with both anesthetic and analgesic effects. First administered to humans in 1964, patients described their ketamine experience as a “feeling of floating in outer space and having no feelings in the limbs” and based on this, ketamine became known as a ‘dissociative anaesthetic, characterized as the “electrophysiological and functional dissociation between thalamocortical and limbic systems. Currently used in clinical and emergency settings as an anesthetic during short procedures, ketamine is utilized in the treatment of numerous forms of chronic pain (postoperative, neuropathic and cancer). Additionally, there has been research into using ketamine in the management of bipolar depression, major depressive disorder (MDD) and treatment resistant depression.

The Effectiveness of Ketamine in Managing Depressive Disorders

Ketamine has been studied for major depressive disorder and bipolar depression. It has:

  • Demonstrated a statistically significant improvement over placebo or midazolam in major depressive disorder,
  • Exhibited a statistically significant improvement over placebo in bipolar depression.

In various studies, ketamine has been found to:

  • Significantly improved depressive symptoms 24 hours post intervention compared with a placebo group, with time-limited,  adverse effects being limited to  feeling strange, poor memory;
  • Display depressive symptom improvement compared with placebo beginning almost immediately and lasting 3 days;
  • Lower the frequency and intensity of  suicidal thoughts when compared to treatment with  Midazolam.
  • Predictors of positive response to a single ketamine infusion in unipolar and bipolar patients are high BMI (body mass index) and lower baseline levels of adiponectin suggesting that metabolic imbalance might be related to ketamine’s antidepressant effect.19,20. It remains unclear as to how repeated ketamine infusions may affect the severity of subsequent episodes of bipolar depression. It is possible that this treatment regimen could decrease the severity of depressive symptoms, as well as improve quality of life and daily functioning.

2. Ketamine Infusion for Bipolar Depression

The administration of low dose ketamine infusion for bipolar depression has studied (Alina Wilkowska, Łukasz Szałach, and Wiesław J Cubała: Ketamine in Bipolar Disorder: A Review: Neuropsychiatr Dis Treat. 2020; 16: 2707–2717) as:

  • A single dose of ketamine: First reported by Berman et al in a placebo-controlled double-blind study conducted among patients with depression, including one bipolar patient) and confirmed in a later placebo-controlled, double-blind crossover study with 18 patients with treatment-resistant MDD (including one with bipolar depression), multiple controlled studies demonstrated the effectiveness of single low-dose ketamine in treatment-resistant cases of bipolar depression.
  • A single dose of ketamine as an adjunct to mood stabilizers: An randomized, placebo-controlled, double-blind, crossover study administered ketamine a single infusion as an adjunct to mood stabilizers to patients with bipolar depression reported an antidepressant effect.  The results were replicated in:
    • A double-blind, randomized, crossover, placebo-controlled study with 15 bipolar patients.
    • An open-label study of 42 patients with bipolar depression found that 52% responded to a single infusion of ketamine.
    • A subsequent study conducted among 53 patients with bipolar depression that showed the rapid antidepressant effect
    • In another study, 23 and 4 patients with unipolar and bipolar depression, respectively, were administered esketamine (0.25mg/kg) and almost half of the patients (48.1%) showed a response within 1 week of treatment while ten patients (37.0%) experienced remission in the same period
  • Multiple doses of ketamine: Studies of multiple administration of ketamine in patients with bipolar depression is limited.  Studies include:
    • A very low dose of sublingual ketamine, administered every 2–3 days/weekly,  Produced rapid and consistent effects, including the improvement of mood level and stability, cognition, and sleep in most patients (77%) with unipolar or bipolar depression
    • The administration of multiple ketamine intravenous infusions in patients with unipolar and bipolar depression resulting in response and remission rates of 68% and 50.5%.
    • 6 low-dose ketamine infusions in 16 bipolar patients reported response and remission rates of  73.7% and 63.2% 24 hours after the last infusion.
    • A trial of 213 TRD patients including 30 patients with bipolar disorder; authors observed rapid anti-depressive and anti-suicidal effects without any significant side effects.
    • A retrospective study on IV ketamine in unipolar and bipolar depression suggests that using ketamine to treat resistant depression has a rapid effect in reducing agitation, irritability, anxiety, and suicidal ideation; it  should be considered in depression with mixed features, which is particularly common in bipolar disorders.

3: Anti-suicidal Effect of Ketamine in Bipolar Depression

Suicide accounts for 15–20% of the deaths of those suffering from bipolar depression; the risk of a suicidal act in biploar patients with mixed or psychotic symptoms is one of the highest of all psychiatric disorders.  While there are no approved pharmacological interventions for suicidality in bipolar disorder, two  studies found that a single intravenous ketamine infusion significantly reduced suicidal ideation in subjects with treatment-resistant depression.  A single dose of ketamine was found that it rapidly reduce suicidal thoughts within 1 day.  The rapid anti-suicidal effect of ketamine is in contrast to the delayed onset of currently available pharmacological treatment; a recent intravenous ketamine trial in depressed patients of six doses of 0.5 mg/kg given three times a week reported a significant reduction in suicidal ideation 24 hours after the first infusion in 57% of patients and in 65% after the sixth infusion.

The anti-suicidal mechanism of ketamine remains unknown and could be attributed to:

  • Plasma kynurenine levels have been implicated in the pathophysiology of suicidal behavior; it has been suggested that ketamine may play a role in its modification.
  • The possible role for microglia:  Based on post-mortem studies of suicidal patients with BD, MDD, and schizophrenia suggested there is the evidence of  the anti-inflammatory effect of ketamine on microglia.
  • It is also possible that ketamine also has an anti- suicidal effect independent of its anti-depressive effects.

4. Understanding the Nervous System

Before diving into how ketamine mediates depression, it is important to understand a little bit of the nervous system structure and how it functions. For our purposes, we are going to limit ourselves to some basic neurological/brain structures, functions and mechanisms so that we get a better understanding of how ketamine works in the human body. At a high level, the human nervous system contains two types of cells: neurons and glial cells. While important, right now all you need to know about glial cells is that they:

  • Protect and hold neurons in place;
  • Supply nutrients to neurons;
  • Insulate neurons with myelin, a fatty substance wrapped around axons that increases the speed and efficiency at which action potentials propagate along the nerve; and
  • Are resident immune cells within the central nervous system.

The Neuron

The fundamental building block of the human nervous system is a neuron, a specialized cell that transmits electrical nerve impulses in responses to neurotransmitters. Neurons have three basic components, the dendrite, the soma and the axons. With the naked eye, you see the nervous system as bundles of nerve fibers, the axon portions of neurons, that spread out from the brain/spinal cord and connect to every part of the body. Neurons transmit/propagate nerve impulses by changing their membrane potential, which is the difference in electric potential between the interior and the exterior of the cell.

The Synapse: Where All The Action Is

Neurons communicate with other cells via a synapse, a cellular membrane to cellular membrane junction that facilitates the transmission of electrical or chemical signals to another neuron or the target cell. At a synapse, the presynaptic neuron comes into close approximation with the postsynaptic cell. The postsynaptic cell membrane contains an extensive array of receptors, protein based cellular structures, that initiate the signaling process. Receptors attach to chemical messengers, like hormones and neurotransmitters, in order to either:

  1. Cause some form of cellular/tissue response/chemical pathway (eg. like a change in the polarity of the cell wall), or,
  2. Inhibit a cellular response (eg limiting production of a cellular metabolite).

Which change the electrical potential of a nerve cell for the purpose of coordinating a biological action. While different types of receptors are found in most cells, each receptor will only bind with specific chemicals, much like how a lock only works with specific keys.

5. Ketamine for Bipolar Depression: Understanding Glutamate

Structural diagram of glutamate
Structural diagram of glutamate

Glutamate, the most abundant excitatory neurotransmitter in the brain, is a powerful neurotransmitter responsible for sending signals between nerve cells, and at normal levels, plays an important role in learning and memory.

The Role of Glutamate in the Brain

Glutamate plays a large role in learning, and memory via a mechanism known as synaptic plasticity, a cellular process that results in lasting changes in the efficacy of neurotransmission. Neuroplasticity is a way for the brain to fine-tune itself for efficiency and happens continually throughout a person’s life as your brain develops with exposure to new data and experiences. It involves altering neural synapses and pathways, neurons, vascular cells, and glial cells. Another part of this process is synaptic pruning, which is the brain’s way of deleting the neural connections that are no longer necessary or useful and strengthening the necessary ones. The human brain decides which connections to prune based on each individuals’ life experiences and how recently connections have been used; neurons that grow weak from underuse die off through the process of apoptosis.

From a more clinical point of view, neuroplasticity, refers to variability in the strength of a signal transmitted through a synapse as a result of:

  • Changes in intracellular signaling cascades and gene regulation,
  • Modifications of synaptic number and strength,
  • Variations in neurotransmitter release, and,
  • Modeling of axonal and dendritic architecture, and, in some areas of the central nervous system, the generation of new neurons.

Neural plasticity, a fundamental mechanism of neuronal adaptation, is thought to be disrupted in those who suffer with depression. The changes in neural plasticity induced by stress and other negative stimuli play a significant role in the onset and development of depression. Antidepressant treatments have also been found to exert their antidepressant effects through regulatory effects on neural plasticity. However, while the detailed mechanisms of neuroplasticity in depression still remain unclear, there is general consensus in the role of glutamate in the process.

Glutamate is abundant in the nervous system and is the:

  • Body’s most prominent neurotransmitter,
  • Brain’s main excitatory neurotransmitter, and
  • Precursor for GABA, the brain’s main inhibitory neurotransmitter.

First identified as a neurotransmitter in 1959, numerous studies demonstrated the role of the glutamatergic system in psychiatric disorders; Initial studies showed elevated glutamate levels in serum and cerebrospinal fluid from patients with mood disorders. The function/dysfunction of the glutamatergic system is hypothesized to play a role in mood disorders in two ways:

  • Elevated glutamate: Abnormally high concentrations of glutamate may overexcite the receiving neuron.
  • Postsynaptic glutamate sensitivity: Glutamate receptors on postsynaptic neurons can be oversensitive, such that a lower concentration threshold of glutamate molecules is needed to excite that cell.

As a result, glutamate activated cells become overactive, which leads to cell damage and/or death. While not simple to interpret, evidence from a range of studies demonstrate the role of the glutamatergic system in major depressive disorders, including bipolar depression and treatment resistant depression. Nuclear resonance studies in those with mood disorders demonstrate altered glutamate level in various regions of the brain; elevated in the occipital cortex and decreased in the anterior cingulate cortex appear to be the most consistent findings in nuclear magnetic resonance spectroscopy. Studies of postmortem tissue from brains of psychiatric patients noted that patients with depression had abnormally high expression levels of many genes that regulate the glutamate system. As research linked mood disorders with the impaired neuroplasticity in various regions of the central nervous system, medical professionals hypothesized that medications capable of increasing resilience to glutamate and modulating its role in neuroplasticity, are promising therapeutics in the treatment of mood disorders.

Is the Glutamate Receptor the Key To Managing Depression?

Ketamine is believed to exert its antidepressant properties through N-methyl-D-aspartate receptor (the NMDA receptor) antagonism. A receptor antagonist is a chemical that unlike an agonist, dampens a biological response by binding to a specific receptor.

The NMDA receptor is one of three types of glutamate receptors found on nerve cells and is activated by the binding action of glutamate. Receptor activation allows positively charged ions to flow through the nerve cell membrane. As previously discussed, research demonstrates that glutamate and the NMDA receptor is very important in neuroplasticity and memory.

Ketamine’s Mechanism of Action in Treating Depression

Ketamine’s inhibition of the N-methyl-D-aspartate glutaminergic receptors has been linked to analgesic, dissociative, and neuroprotective effects. Ketamine also interacts with opioid receptors at high plasma concentrations, causing additional analgesic effects. Ketamine is thought to exert its antidepressant effects through N-methyl-D-aspartate receptor antagonism and possible inhibitory effects on the norepinephrine and serotonin transporter function. Combining all these effects, ketamine administration causes anesthesia, analgesia, tachycardia, increased blood pressure, impaired memory and cognitive function, and visual changes in a dose-dependent manner.

Learn More About Ketamine

Share Frshminds Content With Your Network

About the Author

I've battled depression for most of my adult life, so I speak with the voice and experience of someone who understands the fight.

Earn points.
Unlock rewards.

Earn points to unlock rewards by completing your Frshminds user profile and writing reviews.
Share Your Experience
and start earning today


Leave a Reply

Sign In


Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.